There is mounting evidence that people with severe mental illness have unhealthy lifestyles, high rates of cardiovascular and metabolic diseases, and greater risk of early mortality. This study aimed to assess the cost-effectiveness of a health promotion intervention seeking to improve physical health and reduce substance use in people with psychosis.
Participants with a psychotic disorder, aged 18-65 years old and registered on an enhanced care approach programme or equivalent were recruited from community mental health teams in six mental health trusts in England. Participants were randomisation to either standard community mental health team care (treatment as usual) or treatment as usual with an integrated health promotion intervention (IMPaCT). Cost-effectiveness and cost-utility analyses from health and social care and societal perspectives were conducted alongside a cluster randomised controlled trial. Total health and social care costs and total societal costs at 12 and 15 months were calculated as well as cost-effectiveness (incremental cost-effectiveness ratios and cost-effectiveness acceptability curves) at 15 months based on quality of life (SF-36 mental and physical health components, primary outcome measures) and quality adjusted life years (QALYs) using two measures, EQ-5D-3 L and SF-36. Data were analysed using bootstrapped regressions with covariates for relevant baseline variables.
At 12-15 months 301 participants had full data needed to be included in the economic evaluation. There were no differences in adjusted health and social care costs (£95, 95% CI -£1410 to £1599) or societal costs (£675, 95% CI -£1039 to £2388) between the intervention and control arms. Similarly, there were no differences between the groups in the SF-36 mental component (−0.80, 95% CI -3.66 to 2.06), SF-36 physical component (−0.68, 95% CI -3.01 to 1.65), QALYs estimated from the SF-36 (−0.00, −0.01 to 0.00) or QALYs estimated from the EQ-5D-3 L (0.00, 95% CI -0.01 to 0.02).
Cost-effectiveness acceptability curves for all four outcomes and from both cost perspectives indicate that the probability of the health promotion intervention being cost-effective does not exceed 0.4 for willingness to pay thresholds ranging from £0-£50,000.
Alongside no evidence of additional quality of life/clinical benefit, there is also no evidence of cost-effectiveness.
ISRCTN58667926. Date retrospectively registered: 23/04/2010. Recruitment start date: 01/03/2010.
Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339–47. CrossRefPubMedPubMedCentral
The Schizophrenia Commission. The abandoned illness: a report from the schizophrenia commission. London: Rethink Mental Illness; 2012.
Hert M, Correll CU, Bobes J, Cetkovich-Bakmas MA, Cohen DA, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52–77. CrossRef
Gardner-Sood P, Lally J, Smith S, Atakan Z, Ismail K, Greenwood KE, Keen A, O'Brien C, Onagbesan O, Fung C, Papanastasiou E. Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial. Psychol Med. 2015;45(12):2619–29. CrossRefPubMedPubMedCentral
Verhaeghe N, De Smedt D, De Maeseneer J, Maes L, Van Heeringen C, Annemans L. Cost-effectiveness of health promotion targeting physical activity and healthy eating in mental health care. BMC Public Health. 2014;14(1):1. CrossRef
Meenan RT, Stumbo SP, Yarborough MT, Leo MC, Yarborough BJH, Green CA. An economic evaluation of a weight loss intervention program for people with serious mental illnesses taking antipsychotic medications. Adm Policy Ment Health Ment Health Serv Res. 2016:1–12.
Gaughran F, Stahl D, Ismail K, Atakan Z, Lally J, Gardner-Sood P, Patel A, David A, Hopkins D, Harries B, Lowe P. Improving physical health and reducing substance use in psychosis–randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial. BMC Psychiatry. 2013;13(1):263. CrossRefPubMedPubMedCentral
Gaughran F, Stahl D, Ismail K, Greenwood K, Atakan Z, Gardner-Sood P, Stubbs B, Hopkins D, Patel A, Lally J, Lowe P, Arbuthnot M, Orr D, Eberhard J, David AS, Murray RM, Smith S. Randomised control trial of the effectiveness of an integrated psychosocial health promotion intervention aimed at improving health and reducing substance use in established psychosis (IMPaCT). BMC Psychiatry (in press).
Gaughran F, Stahl D, Ismail K, Greenwood K, Atakan Z, Gardner-Sood P, Stubbs B, Hopkins D, Patel A, Lally J, Lowe P, Arbuthnot M, Orr D, Eberhard J, David AS, Murray RM, Smith S. The IMPACT Programme. HTA. BMC Psychiatry (in press).
Beecham J & Knapp M. Costing psychiatric interventions. In: Thornicroft G (ed). Measuring mental health needs (2nd edition). 2001. Gaskell, London.
Department of Health. NHS reference costs 2010/11. URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_131140
Curtis L. PSSRU: unit costs of Health & Social Care 2012, 2012. Kent: Personal Social Services Research Unit.
Joint Formulary Committee (March 2012). British national formulary. 63rd ed. London: BMJ Group and Pharmaceutical Press; 2012.
Treasury HM. The green book: appraisal and evaluation in central government. London: TSO; 2003.
EuroQol Group. EuroQol: a facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208. CrossRef
Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK population survey. York: University of York; 1995.
Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2003;14:487–96. CrossRef
StataCorp. Stata` 11.2 for Windows. 2011. College Station, TX, StataCorp LP.
Calsyn RJ, Allen G, Morse GA, Smith R, Tempelhoff B. Can you trust self-report data provided by homeless mentally ill individuals? Eval Rev. 1993;17:353–66. CrossRef
Brazier J, Connell J, Papaioannou D, Mukuria C, Mulhern B, Peasgood T, et al. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess. 2014;18(34).
Brown S, Chan K. A randomized controlled trial of a brief health promotion intervention in a population with serious mental illness. J Ment Health. 2006;15(5):543–9. CrossRef
Bartels SJ, Pratt SI, Aschbrenner KA, Barre LK, Jue K, Wolfe RS, Xie H, McHugo G, Santos M, Williams GE, Naslund JA. Clinically significant improved fitness and weight loss among overweight persons with serious mental illness. Psychiatric Services. 2013;64(8):729–36.
Speyer H, Christian Brix Nørgaard H, Birk M, Karlsen M, Storch Jakobsen A, Pedersen K, Hjorthøj C, Pisinger C, Gluud C, Mors O, Krogh J. The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity. World Psychiatry. 2016;15(2):155–65. CrossRefPubMedPubMedCentral
- Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotion
- BioMed Central